WO2023116751A1 - Nanocorps anti-angiopoïétine humaine de type 3 et son utilisation - Google Patents

Nanocorps anti-angiopoïétine humaine de type 3 et son utilisation Download PDF

Info

Publication number
WO2023116751A1
WO2023116751A1 PCT/CN2022/140639 CN2022140639W WO2023116751A1 WO 2023116751 A1 WO2023116751 A1 WO 2023116751A1 CN 2022140639 W CN2022140639 W CN 2022140639W WO 2023116751 A1 WO2023116751 A1 WO 2023116751A1
Authority
WO
WIPO (PCT)
Prior art keywords
nanobody
seq
human
angptl3
fusion protein
Prior art date
Application number
PCT/CN2022/140639
Other languages
English (en)
Chinese (zh)
Inventor
鞠佃文
胡晓植
韩磊
范佳君
巫涛
南艳阳
周楷程
王翰麒
Original Assignee
复旦大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 复旦大学 filed Critical 复旦大学
Publication of WO2023116751A1 publication Critical patent/WO2023116751A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the technical field of biopharmaceuticals, and relates to a nanobody specifically binding to human ANGPTL3; in particular to a preparation of an anti-human ANGPTL3 nanobody and a human immunoglobulin IgG1 Fc fragment fusion protein (anti-hANGPTL3 VHH-Fc); and the Use of the nanobody in the preparation of an ANGPTL3 inhibitor for preventing or treating non-alcoholic fatty liver and atherosclerosis.
  • NAFLD non-alcoholic fatty liver disease
  • Angiopoietin-like protein 3 (ANGPTL3), also known as angiopoietin-5, is a member of the ANGPTL protein family. Studies have found that ANGPTL3 can be cleaved at Arg221 to Ala222 and Arg224 to Thr225, resulting in an N-terminal coiled-coil domain (CCD) and a C-terminal fibrinogen-like domain (FLD) ). Its N-terminal fragment can reversibly inhibit the catalytic activity of LPL, leading to an increase in plasma TG levels; the C-terminal fragment can bind to integrin-binding ⁇ v ⁇ 3 receptors and participate in angiogenesis.
  • CCD N-terminal coiled-coil domain
  • FLD C-terminal fibrinogen-like domain
  • ANGPTL3 is mainly expressed in the liver and rarely expressed in other tissues and organs. More and more evidence shows that ANGPTL3 is related to most lipid metabolism-related diseases, especially hyperlipidemia, coronary heart disease and atherosclerosis very close. Recent studies have shown that ANGPTL3 is highly expressed in the liver of NAFLD patients, and the content of ANGPTL3 in serum is also higher than that of healthy people. Therefore, the levels of TG and LDL-C in plasma can be reduced by inhibiting ANGPTL3, thereby treating NAFLD and atherosclerosis.
  • the inhibitors of ANGPTL3 mainly include monoclonal antibodies, siRNA and antisense oligonucleotides, etc., all of which have played a very good role in reducing TG and LDL-C in plasma.
  • the development of ANGPTL3 antibody drugs is mainly focused on mouse-derived traditional antibodies, and there are more other forms of monoclonal antibodies to be developed.
  • VHH heavy chain variable region
  • Nb nanobody
  • Nanobodies Compared with murine antibodies, nanobodies have stronger resistance to heat and pH, and have the advantages of easy cloning and expression, good solubility, high affinity and easy labeling.
  • VHH germline gene sequence of Nanobodies is highly homologous to human VH3, but its CDR1 and CDR3 regions are slightly longer than those of humans, and the CDR3 region protrudes outward in the tertiary structure, so it is speculated that Nanobodies have higher specificity and affinity for antigen binding than murine antibodies.
  • the small size of nanobodies provides more advantages for their therapeutic functions, it has the disadvantage that small molecular proteins are easily cleared in vivo.
  • the C-terminus of Nanobodies can be linked directly or via a linker peptide to the N-terminus of an IgG Fc fragment of an immunoglobulin.
  • the inventors of the present application intend to provide nanobodies that specifically bind to human ANGPTL3; specifically relate to a fusion protein of anti-human ANGPTL3 nanobody and human immunoglobulin IgG1 Fc fragment (anti-hANGPTL3 VHH-Fc) and its uses.
  • the purpose of the present invention is based on the current state of the art, to provide a nanobody that specifically binds to human ANGPTL3; specifically relates to a fusion protein (anti-hANGPTL3 VHH-Fc) of an anti-human ANGPTL3 nanobody and human immunoglobulin IgG1 Fc segment and its use.
  • One of the objectives of the present invention is to provide a Nanobody specifically binding to ANGPTL3, and to provide the amino acid and nucleotide sequences of the Nanobody or its fragments.
  • the second object of the present invention is to provide a fusion protein of the above Nanobody and human IgG1 Fc fragment, and provide the amino acid and nucleotide sequence of the fusion protein.
  • the third object of the present invention is to provide recombinant vectors and recombinant cells for recombinantly expressing the fusion protein.
  • the fourth object of the present invention is to provide the preparation method and application of the above fusion protein.
  • the fifth object of the present invention is to verify the ability of the fusion protein to neutralize, inhibit, block, eliminate, reduce or interfere with at least one activity of ANGPTL3, especially human ANGPTL3, and the treatment of the fusion protein in NAFLD and atherosclerosis effect.
  • a phage display library of anti-human ANGPTL3 nanobody is constructed, a high-affinity nanobody is screened out, and the nanobody is further connected with a human IgG Fc fragment to make a fusion protein to overcome the problem of rapid metabolism of the nanobody in vivo Disadvantages, experiments have verified the effect of the fusion protein on NAFLD and atherosclerosis models. Since ANGPTL3 inhibitors have significant blood lipid-lowering effects, and nanobodies have high specificity, affinity and stability, the fusion protein of the present invention is expected to become a new drug for the treatment of NAFLD and atherosclerosis, and has huge potential. prospects for clinical application.
  • the present invention adopts the following technical solutions:
  • the invention provides Nanobodies that specifically bind to and neutralize, inhibit, block, abolish, reduce or interfere with at least one activity of ANGPTL3, in particular human ANGPTL3.
  • the activity of ANGPTL3 that can be neutralized, inhibited, blocked, eliminated, reduced or interfered with by the Nanobody includes but not limited to the inhibition of LPL catalytic activity, the effect of inducing angiogenesis and the like.
  • the Nanobodies of the invention are capable of neutralizing, inhibiting, blocking, abrogating, reducing or interfering with the activity of hANGPTL3 by binding to an epitope of hANGPTL3 directly involved in the targeting activity of hANGPTL3.
  • the Nanobodies of the invention are capable of neutralizing, inhibiting, blocking, abrogating, reducing or interfering with the activity of hANGPTL3 by binding to an epitope of hANGPTL3 that is not directly involved in the targeting activity of hANGPTL3, because it The bound antibody or fragment sterically or conformationally inhibits, blocks, abolishes, reduces or interferes with hANGPTL3 targeting activity.
  • the Nanobody of the invention binds to an epitope of hANGPTL3 that is not directly involved in hANGPTL3 targeting activity (e.g. inhibition of LPL activity, induction of angiogenesis, etc.) (i.e.
  • Nanobody results in an increased clearance of hANGPTL3 from the circulation compared to the clearance of hANGPTL3 in the absence of the Nanobody, thereby indirectly inhibiting, blocking, eliminating, reducing or interfering with the activity of hANGPTL3.
  • Combining two or more different non-blocking antibodies that do not compete with each other for specific binding to hANGPTL3 can, inter alia, increase the clearance of hANGPTL3 from the circulation.
  • the present invention provides a Nanobody C44 specifically binding to ANGPTL3, comprising a heavy chain variable region (VHH), the amino acid sequence of which is shown in SEQ ID NO: 1, and the above VHH consists of framework regions (FR1, FR2, FR3 and FR4) and complementarity determining region (CDR1, CDR2 and CDR3), its FR1 amino acid sequence is as described in SEQ ID NO: 2, FR2 amino acid sequence is as described in SEQ ID NO: 3, and FR3 amino acid sequence is as described in SEQ ID NO: 4
  • the amino acid sequence of FR4 is as described in SEQ ID NO: 5, the amino acid sequence of CDR1 is as described in SEQ ID NO: 6, the amino acid sequence of CDR2 is as described in SEQ ID NO: 7, and the amino acid sequence of CDR3 is as described in SEQ ID NO: 8:
  • the present invention also provides the coding nucleotide sequence of the above-mentioned Nanobody C44 such as SEQ ID NO: 9, the above-mentioned C44 Nanobody is composed of framework regions (FR1, FR2, FR3 and FR4) and complementarity determining regions (CDR1, CDR2 and CDR3 ), its FR1 nucleotide sequence is as described in SEQ ID NO: 10, the FR2 nucleotide sequence is as described in SEQ ID NO: 11, the FR3 nucleotide sequence is as described in SEQ ID NO: 12, and the FR4 nucleotide sequence The sequence is as described in SEQ ID NO: 13, the CDR1 nucleotide sequence is as described in SEQ ID NO: 14, the CDR2 nucleotide sequence is as described in SEQ ID NO: 15, and the CDR3 nucleotide sequence is as described in SEQ ID NO: 16 stated.
  • the full-length sequence of the nucleic acid molecule of the present invention or its fragments can usually
  • the invention provides Nanobodies and human IgG1 Fc fragment fusion proteins (Nanobody -Fc).
  • the activity of ANGPTL3 that can be neutralized, inhibited, blocked, eliminated, reduced or interfered by the Nanobody-Fc fusion protein includes but not limited to the inhibition of LPL catalytic activity, the effect of inducing angiogenesis and the like.
  • the Nanobody-Fc fusion protein of the invention is capable of neutralizing, inhibiting, blocking, abrogating, reducing or interfering with the activity of hANGPTL3 by binding to an epitope of hANGPTL3 directly involved in the targeting activity of hANGPTL3.
  • the Nanobody-Fc fusion protein of the invention neutralizes, inhibits, blocks, abolishes, reduces or interferes with the activity of hANGPTL3 by binding to an epitope of hANGPTL3 that is not directly involved in the targeting activity of hANGPTL3 , because the antibody or fragment it binds to inhibits, blocks, eliminates, reduces or interferes with the targeting activity of hANGPTL3 in space or conformation.
  • the Nanobody-Fc fusion protein of the invention binds to an epitope of hANGPTL3 that is not directly involved in hANGPTL3 targeting activity (e.g. inhibition of LPL activity, induction of angiogenesis, etc.) (i.e.
  • the Fc used in the present invention includes but not limited to human IgG1-Fc, human IgG4-Fc, mouse IgG1-Fc, and mouse IgG4-Fc.
  • amino acid sequence of the Fc portion of the immunoglobulin according to the present invention is shown in SEQ ID NO: 17:
  • the nucleotide sequence of the immunoglobulin Fc part of the present invention is shown in SEQ ID NO: 18:
  • the fusion protein of the anti-human ANGPTL3 nanobody C44 and the human IgG1 Fc fragment provided by the present invention, the fusion protein has the nanobody C44 at the N-terminus and the IgG1 Fc fragment at the C-terminus, and its amino acid sequence is shown in SEQ ID NO: 19 Show:
  • the present invention also provides a nucleic acid molecule encoding the gene of the C44-Fc fusion protein, the nucleotide sequence of which is shown in SEQ ID NO:20.
  • the present invention relates to methods and combinations for preventing or attenuating non-alcoholic fatty liver disease in a subject.
  • the methods of the invention comprise administering one or more doses of an angiopoietin-like protein-3 (ANGPTL3) inhibitor to a subject in need thereof.
  • ANGPTL3 angiopoietin-like protein-3
  • the methods of the invention result in a reduction in non-alcoholic fatty liver lipid deposition and a reduction in liver damage in the subject.
  • the present invention relates to methods and combinations for reducing atherosclerotic plaque in a subject.
  • the methods of the invention comprise administering one or more doses of an angiopoietin-like protein-3 (ANGPTL3) inhibitor to a subject in need thereof.
  • ANGPTL3 angiopoietin-like protein-3
  • the methods of the invention result in a decrease in atherosclerotic plaque area, an increase in plaque collagen content, and an increase in plaque stability in the subject.
  • the present invention also provides an expression vector and a host cell containing the gene encoding the above-mentioned anti-hANGPTL3 VHH-Fc fusion protein.
  • the expression vector is a eukaryotic expression vector (pCHO 1.0, pFUSE-hIgG1e1-Fc2, pCDNA 3.1, PTT5, etc.), preferably a eukaryotic expression vector PTT5.
  • the host cells are CHO cells, HEK-293 cells, etc., preferably CHO cells.
  • the present invention provides a preparation method of the above-mentioned ANGPTL3 nanobody: firstly, the ANGPTL3 antigen expressed by CHO cells is used to immunize alpacas, the peripheral blood cells of the immunized alpacas are collected, peripheral blood mononuclear cells (PBMCs) are separated, total RNA is extracted, and Nest -Clone the VHH region of the alpaca heavy chain antibody by PCR technology, insert it into the phage plasmid, construct the phage expression library, and then perform multiple rounds of screening on the ANGPTL3 antigen by phage display technology, and finally sequence the phage obtained from the screening to obtain the nanobody nucleic acid coding sequence.
  • PBMCs peripheral blood mononuclear cells
  • the present invention provides a method for preparing the above-mentioned anti-hANGPTL3 VHH-Fc fusion protein: the method for preparing the anti-hANGPTL3 VHH-Fc fusion protein described in the present invention includes inserting a nucleic acid sequence encoding an anti-hANGPTL3 VHH-Fc fusion protein into into a suitable vector, obtain a corresponding suitable expression vector, and transfect a suitable host cell; and under suitable culture conditions, culture the transfected cell, and isolate and purify the expressed anti-hANGPTL3 VHH-Fc fusion protein therefrom, The affinity and binding constant of the obtained Nanobody-Fc fusion protein were verified by Biacore, and the high-affinity Nanobody-Fc fusion protein was screened out.
  • the conventionally used purification process in the art is adopted, including but not limited to: conventional treatment with protein precipitating agent (salting out method), centrifugation, osmotic bacterial destruction, ultracentrifugation, high performance liquid chromatography (HPLC) , Molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography and other various liquid chromatography techniques and combinations of these methods.
  • the purification process comprises the following steps: (a) collecting the cell culture supernatant; (b) separating Protein A; (c) further purifying with Superdex 200 molecular sieves. Purified by the process selected in the present invention, finally the anti-hANGPTL3 VHH-Fc fusion protein with a purity greater than 95% can be obtained.
  • an anti-human ANGPTL3 nanobody or an antigen-binding fragment thereof which comprises a determinant complementary region and a framework region, and the determinant complementary regions are all composed of CDR1, CDR2 and CDR3, characterized in that:
  • the amino acid sequence of CDR1 is shown in SEQ ID NO: 6;
  • the amino acid sequence of CDR2 is shown in SEQ ID NO: 7;
  • the amino acid sequence of CDR3 is shown in SEQ ID NO: 8.
  • the anti-human angiopoietin 3 Nanobody or its antigen-binding fragment further includes a framework region FR, and the framework region FR is selected from the following group:
  • FR1 amino acid sequence is described in SEQ ID NO:2
  • FR2 amino acid sequence is described in SEQ ID NO:3
  • FR3 amino acid sequence is described in SEQ ID NO:4
  • FR4 amino acid sequence is described in SEQ ID NO:5.
  • amino acid sequence of the anti-human ANGPTL3 Nanobody or its antigen-binding fragment is shown in SEQ ID NO: 1.
  • the anti-human angiopoietin 3 nanobody or antigen-binding fragment thereof includes a monomer, a bivalent body (a bivalent antibody), a tetravalent body (a tetravalent antibody), and/or a multivalent body (multivalent antibody).
  • the anti-human angiopoietin-3 nanobody or antigen-binding fragment thereof includes humanized antibody, camelid antibody, and chimeric antibody.
  • the second aspect of the present invention provides an anti-human ANGPTL3 Nanobody-Fc fragment fusion protein, which is composed of the C-terminus of the Nanobody or antigen-binding fragment described in the first aspect of the present invention directly or through a linker peptide and immunoglobulin IgG
  • the N-terminals of the Fc fragments are connected; the Fc fragment is the Fc fragment of human immunoglobulin IgG1, and its amino acid is shown in SEQ ID NO: 17; the amino acid sequence of the fusion protein is shown in SEQ ID No: 19.
  • the Fc fragment of IgG is selected from the group consisting of Fc fragments of IgG1, IgG2, IgG3, IgG4, or combinations thereof.
  • the third aspect of the present invention provides a nucleic acid molecule encoding the anti-human ANGPTL3 nanobody described in the first aspect of the present invention or its antigen-binding fragment or its Fc fusion protein
  • the nucleic acid molecule sequence encoding CDR1 is as SEQ ID NO As shown in: 14
  • the nucleic acid molecule sequence encoding CDR2 is shown in SEQ ID NO: 15
  • the nucleic acid molecule sequence encoding CDR3 is shown in SEQ ID NO: 16
  • encoding the anti-human angiopoietin 3 Nanobody or its antigen binding The nucleic acid molecule of the fragment is shown in SEQ ID NO:9.
  • nucleic acid molecule encoding the anti-human ANGPTL3 Nanobody-Fc fragment fusion protein according to the second aspect of the present invention is provided; the nucleic acid sequence of the Fc portion of the fusion protein is as shown in SEQ ID NO: 18 Shown; Described fusion protein nucleic acid sequence is shown in SEQ ID No:20.
  • the polynucleotide includes DNA or RNA.
  • the fourth aspect of the present invention provides a recombinant vector comprising the nucleic acid molecule according to the third aspect of the present invention.
  • the recombinant vector is selected from the group consisting of DNA, RNA, viral vector, plasmid, transposon, other gene transfer systems, or combinations thereof.
  • the recombinant vector includes a viral vector, such as lentivirus, adenovirus, AAV virus, retrovirus, or a combination thereof.
  • a viral vector such as lentivirus, adenovirus, AAV virus, retrovirus, or a combination thereof.
  • the fifth aspect of the present invention provides a recombinant cell into which the nucleic acid molecule according to the third aspect of the present invention is introduced, or transfected with the recombinant vector according to the fourth aspect of the present invention.
  • the recombinant cells include prokaryotic cells or eukaryotic cells.
  • the recombinant cells are selected from the group consisting of Escherichia coli, yeast cells, mammalian cells, phage, or combinations thereof.
  • the prokaryotic cells are selected from the group consisting of Escherichia coli, Bacillus subtilis, lactic acid bacteria, Streptomyces, Proteus mirabilis, or combinations thereof.
  • the eukaryotic cells are selected from the group consisting of Pichia pastoris, Saccharomyces cerevisiae, fission yeast, Trichoderma, or combinations thereof.
  • the sixth aspect of the present invention provides a pharmaceutical composition, which comprises one or more of the above-mentioned antibodies, antigen-binding fragments, fusion proteins, nucleic acid molecules, recombinant vectors or recombinant cells, and optionally a pharmaceutical acceptable carrier or excipient.
  • the pharmaceutical composition further comprises one or more drugs selected from HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, bile acid reabsorption inhibitors or drugs that increase lipoprotein catabolism preparation.
  • the pharmaceutical composition further comprises one or more other therapeutic agents selected from statins, niacin, fibrates, anti-hANGPTL4 antibodies and anti-PCSK9 antibodies .
  • the seventh aspect of the present invention provides one or more of the above-mentioned antibodies, antigen-binding fragments, fusion proteins, nucleic acid molecules, recombinant vectors, recombinant cells or pharmaceutical compositions, which are used in the preparation of preventing, alleviating, improving or inhibiting Use in a preparation or medicine for a disease or disorder.
  • the preparation or drug reduces or inhibits ANGPTL3 activity.
  • the eighth aspect of the present invention provides one or more of the above-mentioned antibodies, antigen-binding fragments, fusion proteins, nucleic acid molecules, recombinant vectors, recombinant cells or pharmaceutical compositions used in the preparation and treatment of hyperlipidemia, non-alcoholic fatty Drug use in liver or atherosclerosis.
  • the ninth aspect of the present invention provides an anti-human ANGPTL3 antibody, said antibody comprising one or more anti-human ANGPTL3 nanobodies as described in the first aspect of the present invention.
  • the anti-human ANGPTL3 antibody includes monomers, bivalents (bivalent antibodies), tetravalents (tetravalent antibodies), and/or multivalents (multivalent antibodies), or chimeric Antigen receptor antibody (CAR).
  • the anti-human ANGPTL3 antibody includes one or more VHH chains having the amino acid sequence shown in SEQ ID NO:1.
  • a tenth aspect of the present invention provides a method for producing an anti-human ANGPTL3 Nanobody or its Fc fusion protein, comprising the steps of:
  • step (c) Optionally, purifying and/or modifying the anti-human ANGPTL3 Nanobody or its Fc fusion protein obtained in step (b).
  • the eleventh aspect of the present invention provides a multispecific antibody, said multispecific antibody comprising: the anti-human ANGPTL3 nanobody as described in the first aspect of the present invention, or as described in the ninth aspect of the present invention anti-human ANGPTL3 antibody.
  • the second antigen-binding region is a Nanobody.
  • the multispecific antibody includes one or more second antigen-binding domains.
  • the multispecific antibody further comprises an Fc segment of the antibody.
  • a recombinant protein is provided, and the recombinant protein has:
  • the tag sequence includes Fc tag, HA tag and 6His tag.
  • the recombinant protein specifically binds to human ANGPTL3 protein.
  • the twelfth aspect of the present invention provides a CAR construct, the antigen-binding region of the CAR construct comprises a determinant complementary region, and the determinant complementary region is composed of CDR1, CDR2 and CDR3, and the amino acid of CDR1
  • the sequence is shown in SEQ ID NO: 6; the amino acid sequence of CDR2 is shown in SEQ ID NO: 7; the amino acid sequence of CDR3 is shown in SEQ ID NO: 8
  • the thirteenth aspect of the present invention provides a recombinant immune cell expressing the exogenous CAR construct as described in the twelfth aspect of the present invention.
  • the immune cells are selected from the group consisting of NK cells and T cells.
  • the immune cells are from humans or non-human mammals (such as mice).
  • the fourteenth aspect of the present invention provides an immunoconjugate comprising:
  • a coupling moiety selected from the group consisting of detectable labels, drugs, toxins, cytokines, radionuclides, enzymes, gold nanoparticles/nanorods, nanomagnetic particles, viral coat proteins or VLPs, or combinations thereof .
  • the radionuclides include:
  • isotopes for diagnosis are selected from the group consisting of Tc-99m, Ga-68, F-18, I-123, I-125, I-131, In-111, Ga-67, Cu-64, Zr-89, C-11, Lu-177, Re-188, or combinations thereof; and/or
  • the isotope for treatment is selected from the group consisting of Lu-177, Y-90, Ac-225, As-211, Bi-212, Bi-213, Cs-137, Cr-51, Co-60, Dy-165, Er-169, Fm-255, Au-198, Ho-166, I-125, I-131, Ir-192, Fe-59, Pb-212, Mo-99, Pd- 103, P-32, K-42, Re-186, Re-188, Sm-153, Ra223, Ru-106, Na24, Sr89, Tb-149, Th-227, Xe-133, Yb-169, Yb- 177, or a combination thereof.
  • the coupling moiety is a drug (such as a cytotoxic drug) or a toxin.
  • the cytotoxic drugs are selected from the group consisting of anti-tubulin drugs, DNA minor groove binding agents, DNA replication inhibitors, alkylating agents, antibiotics, folic acid antagonists, antimetabolites, chemotherapy A sensitizer, a topoisomerase inhibitor, a vinca alkaloid, or a combination thereof.
  • the fifteenth aspect of the present invention provides the anti-human ANGPTL3 Nanobody as described in the first aspect of the present invention, the anti-human ANGPTL3 Nanobody-Fc fragment fusion protein as described in the second aspect of the present invention, and the anti-human ANGPTL3 Nanobody-Fc fragment fusion protein as described in the first aspect of the present invention.
  • Use of the anti-human ANGPTL3 antibody described in the ninth aspect, or the immunoconjugate as described in the fourteenth aspect of the present invention (a) for the preparation of a medicament for preventing and/or treating diseases or disorders related to human ANGPTL3 (b) for preparing reagents, detection plates or kits for detecting human ANGPTL3.
  • the detection includes flow detection and cell immunofluorescence detection.
  • the use is diagnostic and/or non-diagnostic, and/or therapeutic and/or non-therapeutic.
  • the sixteenth aspect of the present invention provides a method for detecting human ANGPTL3 protein in a sample, the method comprising the steps of:
  • the method is a non-diagnostic and non-therapeutic method.
  • the seventeenth aspect of the present invention provides a human ANGPTL3 protein detection reagent, the detection reagent comprising:
  • the coupling moiety of the immunoconjugate is an isotope for diagnosis.
  • the detection-acceptable carrier is a non-toxic, inert aqueous carrier medium.
  • the detection reagent is one or more reagents selected from the group consisting of isotopic tracers, contrast agents, flow detection reagents, cellular immunofluorescence detection reagents, magnetic nanoparticles and imaging agent.
  • the detection reagent is used for in vivo detection.
  • the dosage form of the detection reagent is liquid or powder (such as aqueous solution, injection, freeze-dried powder, tablet, buccal preparation, aerosol).
  • the eighteenth aspect of the present invention provides a kit for detecting human ANGPTL3 protein, said kit containing the immunoconjugate described in the fourteenth aspect of the present invention or the detection reagent of the seventeenth aspect of the present invention, and instructions.
  • the instructions describe that the kit is used to non-invasively detect the expression of human ANGPTL3 in the subject to be tested.
  • the invention provides a fusion protein of anti-human ANGPTL3 VHH and anti-human ANGPTL3 VHH-Fc, which can specifically and efficiently bind human ANGPTL3, and can cross-react with mouse ANGPTL3, and has good antigen binding activity and blocking ANGPTL3 protein inhibits the in vitro activity of lipoprotein lipase, thereby effectively reducing the levels of TG, TC and LDL-C in the blood of hyperlipidemia model mice, effectively alleviating liver lipid deposition and liver damage in non-alcoholic fatty liver, effectively Reduces the formation of atherosclerotic plaques.
  • Figure 1 Screening of anti-ANGPTL3 Nanobody and construction and purification of Nanobody-Fc fusion protein, wherein (A) ELISA screening; (B) structure of Nanobody-Fc fusion protein; (C) SDS-page analysis results.
  • FIG. 2 C44-Fc fusion protein neutralizing antigens hANGPTL3(S17-K170)-mFc(A)hANGPTL3(S17-E460)-His10(B)mANGPTL3(S17-T206)-His6(C) and mANGPTL3(S17-T455 )-His10(D) inhibits the in vitro activity of lipoprotein lipase.
  • FIG. 3 C44-Fc fusion protein significantly reduces the levels of TG (A and B), TC (C and D) and LDL (E and F) in the blood of hyperlipidemia model mice.
  • FIG. 4 C44-Fc fusion protein significantly reduces the levels of TG (A), TC (B) and LDL (C) in the blood of non-alcoholic fatty liver model mice.
  • FIG. 5 C44-Fc fusion protein significantly reduces liver lipid deposition and liver damage in non-alcoholic fatty liver model mice, in which (A) body weight; (B) liver morphology; (C) liver weight; (D) liver TG content; (E) liver H&E staining; (F) liver oil red staining; (G) oil red staining (H) ALT (G) AST.
  • FIG. 6 C44-Fc fusion protein significantly reduces blood lipid levels in atherosclerosis model mice, wherein (A) TG; (B) TC; (C) LDL-C; (D) body weight.
  • Figure 7 C44-Fc fusion protein prevents the formation of atherosclerosis in the mouse model, in which (A) plaques at the aortic arch and branches of the mouse; (B) oil red staining in general; (C) aortic sinus Oil red staining of slices; (D) H&E staining of aortic sinus slices; (E) general oil red staining area statistics; (F) oil red staining area statistics of aortic sinus slices; (G) plaque area statistics of aortic sinus slices ( H) Masson staining of aortic sinus sections (I) statistics of plaque collagen content.
  • A plaques at the aortic arch and branches of the mouse
  • B oil red staining in general
  • C aortic sinus Oil red staining of slices
  • D H&E staining of aortic sinus slices
  • E general oil red staining area statistics
  • F oil red staining area statistics of aortic sinus slices
  • H Masson staining of aortic
  • the inventors unexpectedly discovered a class of anti-human ANGPTL3 nanobody or its Fc fusion protein for the first time.
  • the experimental results show that the nanobody of the present invention can specifically and efficiently bind to human ANGPTL3, and It can cross-react with mouse ANGPTL3, has good antigen binding activity and blocks the in vitro activity of ANGPTL3 protein to inhibit lipoprotein lipase.
  • the Fc fusion protein of the nanobody of the present invention not only maintains the biological activity of the VHH fragment of the alpaca anti-human ANGPTL3 heavy chain antibody, but also has a prolonged half-life, and can significantly alleviate the lipid deposition of non-alcoholic fatty liver and reduce atherosclerotic plaque It has a good application prospect in the treatment of non-alcoholic fatty liver and atherosclerosis.
  • the term “comprises” or “includes (comprising)” can be open, semi-closed and closed. In other words, the term also includes “consisting essentially of”, or “consisting of”.
  • the terms “Nanobody of the invention”, “Nanobody of the invention”, “anti-human ANGPTL3 Nanobody of the invention”, “human ANGPTL3 Nanobody of the invention”, “anti-human ANGPTL3 Nanobody”, “human “ANGPTL3 Nanobody” has the same meaning and can be used interchangeably, both refer to Nanobodies that specifically recognize and bind to human ANGPTL3 (including human ANGPTL3).
  • antibody or "immunoglobulin” is a heterotetrameric protein of about 150,000 Daltons with identical structural features, consisting of two identical light (L) chains and two identical heavy chains (H) Composition. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide bonds varies between heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable region (VH) at one end followed by constant regions.
  • VH variable region
  • Each light chain has a variable region (VL) at one end and a constant region at the other end; the constant region of the light chain is opposite the first constant region of the heavy chain, and the variable region of the light chain is opposite the variable region of the heavy chain .
  • VL variable region
  • Specific amino acid residues form the interface between the variable domains of the light and heavy chains.
  • the terms “single domain”, “VHH”, “nanobody”, “heavy chain antibody” (single domain antibody, sdAb, or nanobody nanobody) have the same meaning and are used interchangeably, referring to Cloning the variable region of the antibody heavy chain to construct a Nanobody (VHH) consisting of only one heavy chain variable region, which is the smallest antigen-binding fragment with full functionality.
  • VHH Single domain antibody
  • sdAb single domain antibody, sdAb, or nanobody nanobody
  • variable means that certain portions of the variable regions among antibodies differ in sequence, which contribute to the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout antibody variable domains. It is concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions in the light and heavy chain variable regions. The more conserved portions of the variable domains are called the framework regions (FR).
  • CDRs complementarity determining regions
  • FR framework regions
  • the variable domains of native heavy and light chains each contain four FR regions in a roughly b-sheet configuration connected by three CDRs that form connecting loops, which in some cases may form partial b-sheet structures.
  • the CDRs in each chain are in close proximity through the FR regions and together with the CDRs of the other chain form the antigen-binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Vol. I, pp. 647-669 (1991)).
  • the constant regions are not directly involved in the binding of the antibody to the antigen, but they exhibit different effector functions, for example involved in the antibody-dependent cytotoxicity of the antibody.
  • immunoconjugates and fusion expression products include: drugs, toxins, cytokines (cytokine), radionuclides, enzymes and other diagnostic or therapeutic molecules combined with antibodies or fragments thereof of the present invention to form of conjugates.
  • the present invention also includes cell surface markers or antigens that bind to the anti-human ANGPTL3 antibody or its fragments.
  • variable region is used interchangeably with “complementarity determining region (CDR)”, “determinant complementarity region”.
  • the heavy chain variable region of the antibody includes three complementarity determining regions CDR1, CDR2, and CDR3.
  • the heavy chain of the antibody includes the above-mentioned heavy chain variable region and heavy chain constant region.
  • antibody of the present invention protein of the present invention
  • polypeptide of the present invention are used interchangeably, and all refer to a polypeptide that specifically binds to human ANGPTL3 protein, such as a protein with a heavy chain variable region or peptide. They may or may not contain starting methionine.
  • the invention also provides other proteins or fusion expression products having the antibodies of the invention.
  • the present invention includes any protein or protein conjugates and fusion expression products (i.e., immunoconjugates and fusion expression products) having a heavy chain containing a variable region, as long as the variable region is compatible with the heavy chain of the antibody of the present invention
  • the variable regions are identical or at least 90% homologous, preferably at least 95% homologous.
  • variable regions of the heavy chains of the antibodies of the invention are of particular interest because at least some of them are involved in binding antigen. Therefore, the present invention includes those molecules having antibody heavy chain variable regions with CDRs, as long as the CDRs have more than 90% (preferably more than 95%, most preferably more than 98%) homology to the CDRs identified herein sex.
  • the present invention includes not only complete antibodies, but also fragments of antibodies with immunological activity or fusion proteins formed by antibodies and other sequences. Accordingly, the invention also includes fragments, derivatives and analogs of said antibodies.
  • the fusion protein of the present invention also includes an optional tag sequence (such as 6His tag, GGGS sequence, FLAG tag) that assists expression and/or purification; or includes an optional therapeutic Functional polypeptide molecules or fragments; or optional protein functional domains that assist physicochemical or pharmaceutical (eg, molecules that can prolong the half-life of Nanobodies in vivo, such as Fc fragments, HLE, ABD).
  • an optional tag sequence such as 6His tag, GGGS sequence, FLAG tag
  • optional therapeutic Functional polypeptide molecules or fragments or optional protein functional domains that assist physicochemical or pharmaceutical (eg, molecules that can prolong the half-life of Nanobodies in vivo, such as Fc fragments, HLE, ABD).
  • fragment refers to a polypeptide that substantially retains the same biological function or activity of the antibody of the present invention.
  • the polypeptide fragments, derivatives or analogs of the present invention may be (i) polypeptides having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues It may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a mature polypeptide in combination with another compound (such as a compound that extends the half-life of the polypeptide, e.g.
  • polyethylene glycol polyethylene glycol
  • an additional amino acid sequence fused to the polypeptide sequence such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or with fusion protein formed by 6His tag.
  • an additional amino acid sequence fused to the polypeptide sequence such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or with fusion protein formed by 6His tag.
  • the antibody of the present invention refers to a polypeptide that has human ANGPTL3 binding activity and includes the above-mentioned CDR region.
  • the term also includes variant forms of polypeptides comprising the above CDR regions that have the same function as the antibodies of the present invention. These variations include (but are not limited to): one or more (usually 1-50, preferably 1-30, more preferably 1-20, and most preferably 1-10) amino acid deletions , insertion and/or substitution, and addition of one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminal and/or N-terminal.
  • substitutions with amino acids with similar or similar properties generally do not change the function of the protein.
  • adding one or several amino acids at the C-terminus and/or N-terminus usually does not change the function of the protein.
  • the term also includes active fragments and active derivatives of the antibodies of the invention.
  • Variants of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, DNA hybrids that can hybridize with the DNA encoding the antibody of the present invention under high or low stringency conditions
  • the encoded protein, and the polypeptide or protein obtained by using the antiserum against the antibody of the present invention.
  • the invention also provides other polypeptides, such as fusion proteins comprising Nanobodies or fragments thereof.
  • the invention also includes fragments of the Nanobodies of the invention.
  • the fragment has at least about 50 contiguous amino acids, preferably at least about 50 contiguous amino acids, more preferably at least about 80 contiguous amino acids, and most preferably at least about 100 contiguous amino acids of an antibody of the invention.
  • “conservative variants of the antibody of the present invention” refer to at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acid sequences compared with the amino acid sequence of the antibody of the present invention.
  • An amino acid is replaced by an amino acid with similar or similar properties to form a polypeptide.
  • These conservative variant polypeptides are preferably produced by amino acid substitutions according to Table A.
  • the present invention also provides polynucleotide molecules encoding the above-mentioned antibodies or fragments or fusion proteins thereof.
  • a polynucleotide of the invention may be in the form of DNA or RNA.
  • Forms of DNA include cDNA, genomic DNA or synthetic DNA.
  • DNA can be single-stranded or double-stranded.
  • DNA can be either the coding strand or the non-coding strand.
  • a polynucleotide encoding a mature polypeptide of the present invention includes: a coding sequence that encodes only the mature polypeptide; a coding sequence for the mature polypeptide and various additional coding sequences; a coding sequence for the mature polypeptide (and optional additional coding sequences) and non-coding sequences .
  • polynucleotide encoding a polypeptide may include a polynucleotide encoding the polypeptide, or may also include additional coding and/or non-coding sequences.
  • the present invention also relates to polynucleotides which hybridize to the above-mentioned sequences and which have at least 50%, preferably at least 70%, more preferably at least 80% identity between the two sequences.
  • the invention particularly relates to polynucleotides which are hybridizable under stringent conditions to the polynucleotides of the invention.
  • stringent conditions refer to: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2 ⁇ SSC, 0.1% SDS, 60°C; or (2) hybridization with There are denaturing agents, such as 50% (v/v) formamide, 0.1% calf serum/0.1% Ficoll, 42°C, etc.; or (3) only if the identity between the two sequences is at least 90%, more Preferably, hybridization occurs above 95%.
  • the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
  • the full-length nucleotide sequence of the antibody of the present invention or its fragments can usually be obtained by PCR amplification, recombination or artificial synthesis.
  • a feasible method is to use artificial synthesis to synthesize related sequences, especially when the fragment length is short. Often, fragments with very long sequences are obtained by synthesizing multiple small fragments and then ligating them.
  • the coding sequence of the heavy chain and an expression tag (such as 6His) can also be fused together to form a fusion protein.
  • biomolecules nucleic acid, protein, etc.
  • the biomolecules involved in the present invention include biomolecules in an isolated form.
  • the DNA sequence encoding the protein of the present invention (or its fragment, or its derivative) can be obtained completely through chemical synthesis. This DNA sequence can then be introduced into various existing DNA molecules (or eg vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequences of the invention by chemical synthesis.
  • the present invention also relates to vectors comprising the above-mentioned appropriate DNA sequences and appropriate promoter or control sequences. These vectors can be used to transform appropriate host cells so that they express the protein.
  • the host cell may be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell.
  • a prokaryotic cell such as a bacterial cell
  • a lower eukaryotic cell such as a yeast cell
  • a higher eukaryotic cell such as a mammalian cell.
  • Representative examples are: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf9; animal cells of CHO, COS7, 293 cells, etc.
  • Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art.
  • competent cells capable of taking up DNA can be harvested after the exponential growth phase and treated with the CaCl2 method using procedures well known in the art. Another method is to use MgCl2 . Transformation can also be performed by electroporation, if desired.
  • DNA transfection methods can be used: calcium phosphate co-precipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
  • the obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention.
  • the medium used in the culture can be selected from various conventional media according to the host cells used.
  • the culture is carried out under conditions suitable for the growth of the host cells. After the host cells have grown to an appropriate cell density, the selected promoter is induced by an appropriate method (such as temperature shift or chemical induction), and the cells are cultured for an additional period of time.
  • the recombinant polypeptide in the above method can be expressed inside the cell, or on the cell membrane, or secreted outside the cell.
  • the recombinant protein can be isolated and purified by various separation methods by taking advantage of its physical, chemical and other properties, if desired. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to: conventional refolding treatment, treatment with protein precipitating agents (salting out method), centrifugation, osmotic disruption, supertreatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption layer Analysis, ion exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
  • the antibodies of the invention can be used alone, or combined or conjugated with a detectable label (for diagnostic purposes), a therapeutic agent, a PK (protein kinase) modifying moiety, or a combination of any of these.
  • Detectable labels for diagnostic purposes include, but are not limited to, fluorescent or luminescent labels, radioactive labels, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or substances capable of producing a detectable product. enzyme.
  • Therapeutic agents that can be combined or coupled with the antibody of the present invention include but are not limited to: 1. Radionuclide; 2. Biological toxicity; 3. Cytokines such as IL-2, etc.; 4. Gold nanoparticles/nanorods; 5. Viruses Particles; 6. Liposomes; 7. Nanomagnetic particles; 8. Prodrug activating enzymes (for example, DT-diaphorase (DTD) or biphenylhydrolase-like protein (BPHL)), etc.
  • DTD DT-diaphorase
  • BPHL biphenylhydrolase-like protein
  • the present invention also provides a composition.
  • the composition is a pharmaceutical composition, which contains the above-mentioned antibody or its active fragment or its fusion protein, and a pharmaceutically acceptable carrier.
  • these materials can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is usually about 5-8, preferably about 6-8, although the pH value can be changed according to the Depending on the nature of the substance formulated and the condition to be treated.
  • the formulated pharmaceutical composition can be administered by conventional routes, including but not limited to: intraperitoneal, intravenous, or topical administration.
  • the pharmaceutical composition of the present invention contains a safe and effective amount (such as 0.001-99wt%, preferably 0.01-90wt%, more preferably 0.1-80wt%) of the above-mentioned Nanobody (or its conjugate) of the present invention and pharmaceutically acceptable carrier or excipient.
  • Such carriers include, but are not limited to: saline, buffer, dextrose, water, glycerol, ethanol, and combinations thereof.
  • the pharmaceutical formulation should match the mode of administration.
  • the pharmaceutical composition of the present invention can be prepared in the form of injection, for example, by conventional methods using physiological saline or aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as injections and solutions are preferably produced under sterile conditions.
  • the active ingredient is administered in a therapeutically effective amount, for example about 10 micrograms/kg body weight to about 50 mg/kg body weight per day.
  • the polypeptides of the invention can also be used with other therapeutic agents.
  • a safe and effective amount of the immunoconjugate is administered to the mammal, wherein the safe and effective amount is usually at least about 10 micrograms/kg body weight, and in most cases no more than about 50 mg/kg body weight, Preferably the dose is about 10 micrograms/kg body weight to about 10 mg/kg body weight.
  • the route of administration and the health status of the patient should also be considered for the specific dosage, which are within the skill of skilled physicians.
  • the Nanobody has a detectable label. More preferably, the label is selected from the group consisting of isotopes, colloidal gold labels, colored labels or fluorescent labels.
  • colloidal gold labeling can be performed using methods known to those skilled in the art.
  • the nanobody of human ANGPTL3 is labeled with colloidal gold to obtain a colloidal gold-labeled nanobody.
  • the present invention also provides a kit containing the antibody (or its fragment) or detection plate of the present invention.
  • the kit further includes a container, instructions for use, buffer and the like.
  • the present invention also provides a detection kit for detecting the level of human ANGPTL3, which includes an antibody that recognizes human ANGPTL3 protein, a lysis medium for dissolving samples, general reagents and buffers required for detection, such as various buffers , detection labels, detection substrates, etc.
  • the test kit may be an in vitro diagnostic device.
  • VHH V region of the alpaca heavy chain antibody
  • the culture was divided into centrifuge tubes, centrifuged at 25°C and 5000r/min for 10min, and the cell pellet was collected and resuspended in 50mL 2 ⁇ YT-AK liquid medium, and placed at 30°C and 230r/min Incubate overnight with shaking.
  • the overnight culture was centrifuged at 10,000 r/min at 4°C for 20 min, the supernatant was transferred to a new centrifuge tube, 1/5 volume of PEG/NaCl was added, mixed well, placed at 4°C and allowed to stand for 2 h. Then, at 4°C, centrifuge at 10,000r/min for 20min to remove the supernatant, resuspend the pellet in 1mL PBS, add 1/5 volume of PEG/NaCl, mix well and place at 4°C for 1h.
  • Embodiment 3 construct and purify anti-hANGPTL3 VHHs-Fc fusion protein
  • the gene sequence of the Fc segment of human immunoglobulin is fused with the gene sequence of 9 anti-ANGPTL3 nanometer monoclonal antibodies screened in the above-mentioned Example 2 (as shown in FIG. 1B ), to obtain anti-ANGPTL3 nanometer monoclonal antibody and human IgG Fc segment
  • the gene sequence of the fusion protein is obtained.
  • the gene sequence of the bifunctional protein was reacted with the PTT5 plasmid at a molar ratio of 1:3, and it was constructed into the PTT5 plasmid.
  • the ExpiFectamine TM CHO/plasmid DNA complex (plasmid DNA concentration: 1 ⁇ g/mL) was prepared using pre-cooled OptiPRO TM medium (4° C.), and incubated at room temperature for 5 min. After shaking and culturing at 37°C and 8% CO 2 for 22 h, 24 mL of ExpiFectamine TM CHO enhancer and 24 mL of ExpiCHO TM adjuvant were added to the culture flask, and the culture was continued for 7 days. After being centrifuged at 3000 g for 10 min, the culture supernatant was collected by filtration with a 0.22 ⁇ m filter membrane, and its protein content was detected by the BCA method.
  • hANGPTL3 Human and mouse fragments or full-length ANGPTL3 proteins were captured on the surface of the CM5 chip, and the captured recombinant proteins were: hANGPTL3 containing 17-170 amino acids of mouse IgG1-Fc [hANGPTL3(17-170)-Fc], containing Full-length mature human ANGPTL3 containing a C-terminal decahistidine tag [hANGPTL3(17-460)-His; R&D Systems, MN; Cat. No. 3829-AN], containing a C-terminal decahistidine tag [mANGPTL3( 17-455)-His; R&D Systems, MN; Cat. No.
  • ANGPTL3 full-length mature ANGPTL3 derived from Mus musculus and containing a C-terminal hexahistidine tag [mANGPTL3(17-206)-His ; Novoprotein; catalog number Q9Y5C1] of ANGPTL3 derived from amino acids 17-206 of Mus musculus.
  • C27-Fc and C44-Fc were injected on the captured protein surface for 120 min at a flow rate of 30 ⁇ L/min, and the dissociation of the complex was observed for 480 s or 900 s.
  • the affinity of C44-Fc is between 0.1402nM-0.3036nM
  • the affinity of C27-Fc The affinity is between 0.01811nM-8.202nM.
  • Example 5 In vitro activity test of anti-hANGPTL3 VHH-Fc fusion protein neutralizing ANGPTL3 protein to inhibit lipoprotein lipase
  • Lipoprotein lipase is an important enzyme in the process of lipid metabolism, which can hydrolyze triglycerides, and the N-terminal helical coil region of ANGPTL3 can inhibit its activity.
  • the affinity of C44-Fc to human and mouse full-length ANGPTL3, and the N-terminal helical coil region of mouse ANGPTL3 is significantly higher than that of C27-Fc, so C44-Fc is selected to inhibit the LPL activity induced by ANGPTL3 Dropped cell-free experiments.
  • ANGPTL3 proteins were used to measure the inhibition of C44-Fc on four ANGPTL3 activities, including: hANGPTL3(17-170)-Fc, hANGPTL3(17-460 )-His, mANGPTL3(17-455)-His and mANGPTL3(17-206)-His.
  • 0.2 nM bovine LPL, 0.1 ⁇ M human ApoC II, and 0.2 mg/mL BSA were premixed in PBS, and then serially diluted ANGPTL3 recombinant protein or ANGPTL3 recombinant protein and serially diluted C44-Fc fusion protein were added, After incubating at room temperature for 10 minutes, it was detected with the kit, and the fluorescence intensity was measured at 482nm/515nm (excitation/emission) with a BioTek multifunctional microplate reader, and the fluorescence intensity was proportional to the LPL activity. As shown in Figure 2 and Table 3, the IC 50 of C44-Fc is between 1.6nM-5.4nM, and the affinity of C27-Fc is between 0.01811nM-8.202nM.
  • C44-Fc exerts similar inhibitory effects on human and mouse ANGPTL3, so C57Bl/6 mice were selected for pharmacodynamic evaluation.
  • C57Bl/6 mice were first fed with a high-fat and high-cholesterol diet (Teklad TD.90221, containing 15.8% fat, 1.25% cholesterol and 0.5% bile salt) for 4 weeks, fasted for 4 hours, and blood was taken to measure the total cholesterol in the serum Increased from 3.77mmol/L to 9.21mmol/L, LDL-C increased from 0.85mmol/L to 2.07mmol/L, blood lipid significantly increased more than 2 times.
  • a high-fat and high-cholesterol diet Teklad TD.90221, containing 15.8% fat, 1.25% cholesterol and 0.5% bile salt
  • C44-Fc was injected subcutaneously at doses of 10 mg/kg and 25 mg/kg, blood was taken after fasting for 4 hours after administration as day 0, and blood was taken after fasting for 4 hours on the 1st, 4th, 7th, and 12th respectively , Determination of serum TG, TC, LDL-C content.
  • the serum TG content was significantly reduced by 44%
  • the serum TC content was significantly reduced by 36%
  • the serum LDL-C content was significantly reduced by 50%.
  • mice were first fed with a high-fat and high-cholesterol diet (Teklad TD.90221, containing 15.8% fat, 1.25% cholesterol and 0.5% bile salt) for 8 weeks, and blood was taken after 4 hours of fasting to measure the Blood lipids increased significantly, in which total cholesterol increased from 4.3mmol/L to 10.6mmol/L, and LDL-C increased from 0.41mmol/L to 2.3mmol/L. Afterwards, the mice were subcutaneously injected with C44-F at a dose of 25 mg/kg every week and their body weight was recorded. After 4 hours of fasting, the contents of TG, TC and LDL-C in the serum of the mice were determined.
  • a high-fat and high-cholesterol diet Teklad TD.90221, containing 15.8% fat, 1.25% cholesterol and 0.5% bile salt
  • ApoE -/- mice were first fed with a high-fat and high-cholesterol diet (Teklad TD.90221, containing 15.8% fat, 1.25% cholesterol and 0.5% bile salts) for 7 weeks, and blood was taken after fasting for 4 hours to measure blood lipids Significantly increased, in which total cholesterol increased from 24.9mmol/L to 56.9mmol/L, and LDL-C increased from 17.4mmol/L to 22.7mmol/L. After that, C44-Fc was subcutaneously injected weekly at a dose of 25 mg/kg and the body weight of the mice was recorded.
  • a high-fat and high-cholesterol diet Teklad TD.90221, containing 15.8% fat, 1.25% cholesterol and 0.5% bile salts
  • C44-Fc After weekly subcutaneous injection of C44-Fc for 4 days, they were fasted for 4 hours and the contents of TG, TC and LDL-C in the mouse serum were determined. As shown in Figure 6, the injection of C44-Fc significantly reduced the serum levels of ApoE -/- mice The content of TG, TC and LDL-C. After 5 weeks of administration, the mice were euthanized, the mice were dissected, and the aortic arch and three branches were separated, washed with saline and carefully stripped of the fat on the outside. As shown in Figure 7A, the injection of C44-Fc significantly reduced plaques form.

Abstract

La présente invention relève du domaine biopharmaceutique. La présente invention concerne un nanocorps anti-ANGPTL3 humaine. La présente invention concerne en outre un procédé de préparation d'une protéine de fusion (anti-hANGPTL3 VHH-Fc) formée par liaison du nanocorps à un fragment Fc d'IgG1 humaine. De plus, la présente invention concerne en outre l'utilisation de la protéine de fusion anti-hANGPTL3 VHH-Fc dans la stéatose hépatique non alcoolique et l'athérosclérose. La protéine de fusion selon la présente invention maintient l'activité biologique du fragment VHH d'un anticorps à chaîne lourde anti-ANGPTL3 humaine alpaca, introduit le fragment Fc pour prolonger sa demi-vie, atténue de manière significative le dépôt lipidique de la stéatose hépatique non alcoolique, réduit la formation de plaques athérosclérotiques, et présente de bonnes perspectives d'application.
PCT/CN2022/140639 2021-12-21 2022-12-21 Nanocorps anti-angiopoïétine humaine de type 3 et son utilisation WO2023116751A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111569804.X 2021-12-21
CN202111569804.XA CN116284377A (zh) 2021-12-21 2021-12-21 抗人血管生成素3纳米抗体及其应用

Publications (1)

Publication Number Publication Date
WO2023116751A1 true WO2023116751A1 (fr) 2023-06-29

Family

ID=86798288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/140639 WO2023116751A1 (fr) 2021-12-21 2022-12-21 Nanocorps anti-angiopoïétine humaine de type 3 et son utilisation

Country Status (2)

Country Link
CN (1) CN116284377A (fr)
WO (1) WO2023116751A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101855241A (zh) * 2006-12-08 2010-10-06 莱克康制药公司 针对angptl3的单克隆抗体
CN103732624A (zh) * 2011-06-17 2014-04-16 瑞泽恩制药公司 抗angptl3抗体及其用途
CN110938144A (zh) * 2019-11-27 2020-03-31 上海市闵行区中心医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
CN112062844A (zh) * 2019-06-10 2020-12-11 山东博安生物技术有限公司 抗angptl3抗体及其用途
WO2021147984A1 (fr) * 2020-01-22 2021-07-29 江苏恒瑞医药股份有限公司 Anticorps anti-angptl3 et son utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101855241A (zh) * 2006-12-08 2010-10-06 莱克康制药公司 针对angptl3的单克隆抗体
CN103732624A (zh) * 2011-06-17 2014-04-16 瑞泽恩制药公司 抗angptl3抗体及其用途
CN112062844A (zh) * 2019-06-10 2020-12-11 山东博安生物技术有限公司 抗angptl3抗体及其用途
CN110938144A (zh) * 2019-11-27 2020-03-31 上海市闵行区中心医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
WO2021147984A1 (fr) * 2020-01-22 2021-07-29 江苏恒瑞医药股份有限公司 Anticorps anti-angptl3 et son utilisation

Also Published As

Publication number Publication date
CN116284377A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
JP7336122B2 (ja) 抗ｖｅｇｆ単一ドメイン抗体およびその応用
WO2017157334A1 (fr) Nanocorps anti-pd-l1, séquence de codage et utilisation associées
JP2019047807A (ja) Ｐｄｇｆ受容体ベータ結合ポリペプチド
US20230399395A1 (en) Anti-il5 nanoantibody and use thereof
EP4257605A1 (fr) Nanocorps anti-tslp et son utilisation
WO2022143550A1 (fr) Molécule de liaison à la mésothéline et son utilisation
CN114685666B (zh) 抗间皮素纳米抗体及其应用
JP7387206B2 (ja) 抗ｉｌ－４ｒ単一ドメイン抗体およびその適用
WO2023125842A1 (fr) Développement d'un nouvel anticorps à domaine unique anti-upar
EP4365202A1 (fr) Anticorps à domaine unique anti-trop2 et son utilisation
WO2023116751A1 (fr) Nanocorps anti-angiopoïétine humaine de type 3 et son utilisation
CN114685667B (zh) 间皮素结合分子及其应用
US20230002503A1 (en) Nano-antibody targeting caix antigen and application thereof
WO2024099310A1 (fr) Séquence de nanocorps à action prolongée anti-il-13 et son utilisation
JP7315259B2 (ja) 百日咳毒素結合タンパク質
CN115873113A (zh) 靶向CaSR的纳米抗体及其制备方法和应用
TW202409074A (zh) 鬆弛素或類似物的融合蛋白及其醫藥用途
CN118027202A (en) Antibodies that bind SLC13A5 membrane proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22910063

Country of ref document: EP

Kind code of ref document: A1